SECURITIES AND EXCHANGE COMMISSION
                  Washington, D.C.  20549


                          FORM 8-K
        Current Report Pursuant to Section 13 or 15(d) of
                 The Securities Act of 1934


        Date of Report (Date of earliest event reported):
                      January 28, 1999


                 Bausch & Lomb Incorporated
- -----------------------------------------------------------
    (Exact name of registrant as specified in its charter)

            New York       1-14105        16-0345235
            --------       -------        ----------
        (State or other   Commission    (IRS Employer
        jurisdiction of   File Number)  Identification No.)
        incorporation)


   One Bausch & Lomb Place, Rochester, New York 14604-2701
- -----------------------------------------------------------
     (Address of principal executive offices)   (Zip Code)


     Registrant's telephone number, including area code:
                       (716) 338-6409

                       Not Applicable
- -----------------------------------------------------------
    (Former name or former address, if changed since last
                          report.)



ITEM 5.  OTHER EVENTS

On January 28, 1999 the Company announced that it is 
amending its financial results for the first three quarters 
of 1998 in light of recently published guidance from the 
Securities and Exchange Commission concerning the valuation 
of acquired in-process research and development projects.

Generally accepted accounting principles governing business 
acquisitions require that a portion of the purchase price 
for Chiron Vision Corporation and Storz Instrument Company 
be allocated to in-process research and development projects 
underway at the acquired businesses, and immediately charged 
to expense.  While the original charge for in-process R&D 
followed commonly-used valuation methods, recent public 
statements made by the Chief Accountant of the SEC provide 
public companies with new guidance on the valuation 
methodology to be used for such charges.  Using this new 
guidance, the company has recalculated and reduced the 
charge it reported with its results for the first quarter of 
1998 for the in-process R&D acquired with Chiron Vision and 
Storz.

The revised charge is $24.6 million after-tax, or $0.44 per 
share, as compared with the initially reported amount of 
$51.0 million after-tax, or $0.92 per share.  On a pre-tax 
basis, the revised charge is $41.0 million, as compared with 
the original amount of $85.0 million.  The recalculation 
results in slightly higher quarterly goodwill amortization 
expense for 1998, reducing net earnings in the fourth 
quarter by less than $0.3 million after taxes, or less than 
$0.01 per share, and by $0.9 million after taxes, or $0.02 
per share, for the full year.

The Company will amend its form 10-Q filings for 1998 to 
reduce the first quarter in-process R&D charge and adjust 
the goodwill amortization.  The Company expects to file 
these amendments prior to the filing of its 1998 Annual 
Report on Form 10-K.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act 
of 1934, the Registrant has duly caused this report to be 
signed on its behalf by the undersigned thereunto duly 
authorized.

Dated:  February 1, 1999

Bausch & Lomb Incorporated

By:/s/[Stephen C. McCluski]
- ---------------------------
Senior Vice President and
Chief Financial Officer